$ News

Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price Surge

GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play

GSK to buy Canada's 35Pharma for $950 million

RAPT THERAPEUTICS INC (NASDAQ:RAPT) Shows High Technical and Pattern Scores Ahead of Potential Breakout

GSK Extends RSV Reach And Adds Food Allergy Assets With RAPT Deal

Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge

Barclays Downgrades RAPT Therapeutics to Equal-Weight, Announces $58 Price Target

Leerink Partners Downgrades RAPT Therapeutics to Market Perform, Announces $58 Price Target

S&P 500 Records Worst Session Since October: Investor Sentiment Dips, Fear & Greed Index In 'Neutral' Zone

Why Rapt Therapeutics Stock Soared Today

GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug

Wells Fargo Downgrades RAPT Therapeutics to Equal-Weight, Announces $58 Price Target

LifeSci Capital Downgrades RAPT Therapeutics to Market Perform

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

TD Cowen Downgrades RAPT Therapeutics to Hold

HC Wainwright & Co. Downgrades RAPT Therapeutics to Neutral, Announces $58 Price Target

GSK acquires RAPT Therapeutics for $2.2bn

Biggest Market Mover: RAPT Therapeutics Stock Soars After GSK $2.2B Acquisition Deal